CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1643279
This article is part of the Research TopicPredictive Biomarkers to Immune Checkpoint Inhibitors in Lung CancerView all articles
When Dual Immune Checkpoint Blockade Strikes Back: Cadonilimab-Induced Hypersensitivity in Solid Tumors -A Case Series and Review
Provisionally accepted- 1The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
- 2Zhejiang University Cancer Center, Haining, China
- 3Zhejiang University, Hangzhou, China
- 4Wenzhou Medical University Renji College, Wenzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but immune-related hypersensitivity reactions remain a clinical concern. Cadonilimab, a novel PD-1/CTLA-4 bispecific antibody, has demonstrated encouraging antitumor efficacy across various solid tumors; however, hypersensitivity or infusion-related reactions may occasionally occur.We herein report five cases of cadonilimab-induced allergic or infusion-related reactions in patients with different advanced solid tumors. Clinical manifestations ranged from mild skin rash to severe anaphylaxis with hypotension. All patients were managed promptly with individualized anti-allergic interventions, and some were able to safely continue therapy with modified infusion protocols.The series emphasizes the importance of early identification and tailored management of hypersensitivity reactions during cadonilimab treatment. Additionally, a comprehensive literature review was conducted summarizing current clinical trials, case reports, and real-world evidence regarding cadonilimab's efficacy and safety across multiple cancer types.Our findings highlight both the potential risks and manageable nature of cadonilimab-induced hypersensitivity, supporting its continued clinical application with appropriate monitoring and management strategies.
Keywords: Cadonilimab, Hypersensitivity reaction, Infusion-related reaction, Immune checkpoint inhibitor, case report, literature review
Received: 08 Jun 2025; Accepted: 14 Jul 2025.
Copyright: © 2025 Song, Jin, Fu and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yinuo Tan, Zhejiang University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.